CYTOKINETICS INC (CYTK) — SEC Financial Statements & Analysis

CYTOKINETICS INC (CYTK) is a pharmaceutical preparations company. CYTOKINETICS INC trades on Nasdaq as: CYTK. CYTOKINETICS INC (CYTK)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, CYTOKINETICS INC carries a market cap of $11.25B, a P/E ratio of -12.59x, a P/B ratio of -64.86x, a P/S ratio of 166.28x, an enterprise value of $11.27B, and an EV/EBITDA multiple of -16.21x. On profitability, it posts a gross margin of 146.70%, an operating margin of -1046.12%, a net margin of -1321.12%, a Return on Equity (ROE) of 329.76%, and a Return on Assets (ROA) of -56.76%. Per share, it reports EPS of $-6.77, diluted EPS of $-6.77, free cash flow per share of $-4.40, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -21.07% year-over-year, net income growth of 47.45% year-over-year, and EPS growth of 33.35% year-over-year. On the balance sheet, it maintains a current ratio of 6.66x, a quick ratio of 6.56x, working capital of $1.03B, a debt-to-equity ratio of -12.09x, a debt ratio of 1.09, an interest coverage ratio of -20.52x, free cash flow of $-580.72M (TTM), and net debt of $20.29M. Figures sourced from SEC EDGAR.

Market Cap

$11.25B

P/E TTM

-12.59x

EPS TTM

$-6.77

P/B TTM

-64.86x

ROE TTM

329.76%

ROA TTM

-56.76%

Debt To Equity

-12.09x

Free Cash Flow TTM

$-580.72M

Net Revenue TTM Growth 1Y

-21.07%

Data as of 2026-06-30 · Source: SEC EDGAR